Background

Rheumatoid Arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks joint tissues, causing inflammation and pain. Conventional treatments have focused on managing symptoms using disease-modifying antirheumatic drugs or biological agents such as tumor necrosis factor (TNF) inhibitors. However, some patients remain in a non-responsive state, experiencing joint destruction and physical disability despite existing therapies.

Efforts to eliminate B-cells (B-cell), which drive autoimmune responses, have continued. Antibody-based drugs have been introduced to deplete B-cells, but it has been difficult to completely remove pathogenic B-cells hiding deep within lymph nodes or joint tissues. Residual cells often re-proliferate, leading to recurring disease cycles. For severe patients who struggle to avoid joint damage despite lifelong medication, an alternative approach that resets the immune system itself has been urgently needed.

Key Findings

Researchers at Charité – Universitätsmedizin Berlin applied chimeric antigen receptor T-cell (CAR-T) technology, originally used to target cancer cells, to autoimmune diseases. In the phase 1 part of the COMPARE clinical trial, the team administered CD19-targeting CAR-T cells to six patients with severe seropositive RA who had not responded to existing treatments. The therapy was genetically engineered to precisely identify and eliminate autoreactive B-cells in patients.

The results showed clear clinical improvement in all six patients, with reduced joint pain and inflammation. The administered CAR-T cells penetrated deep into lymphoid tissues and synovial membranes, effectively clearing pathogenic B-cells. After depletion, the immune system was observed to reset, allowing normal B-cells to regenerate. Fortunately, no severe adverse effects such as cytokine release syndrome (CRS) or neurotoxicity were reported.

Implications and Outlook

This study is being praised for expanding cell therapy beyond blood cancer treatment to address the root causes of chronic autoimmune diseases. It demonstrated that a single infusion could reset the immune system, enabling long-term remission without medication. This therapeutic mechanism is expected to broaden research into various autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, where B-cells malfunction.

However, challenges remain before commercialization. As the results were observed in a small group of six patients over a short period, the long-term efficacy over several years remains to be confirmed. Additionally, the CAR-T manufacturing process, which requires individual cell processing for each patient, presents challenges in cost and complexity. The reason the research team is initiating a phase 2 clinical trial is to address these issues by comparing the treatment with existing B-cell-targeting antibody therapies.